TICKERNERD
Menu
TKNOTKNOHealthcare · Drug Manufacturers - Specialty & Generic

TKNO Stock Forecast: Alpha Teknova, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$6.49
−0.61% on the day

The 7 Wall Street analysts covering Alpha Teknova, Inc. hold a median 12-month price target of $8 — +23.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 8 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$346.3M
Ticker Nerd rank
94 / 100
Median analyst target
$8.00
Analysts covering
7
Total return, dividends reinvested
1W
+29.8%
1M
+19.5%
YTD
+70.8%
1Y
+49.5%
From 52W high
−0.6%
From 52W low
+226.1%
$1.99
$6.53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TKNO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alpha Teknova, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
95
Accruals
87
Quality
78
Issuance
69
Growth
67
Size
59
Value
59
Momentum
57
Volatility
32

Revisions (95): Analysts have, on balance, been raising their forecasts.

Volatility (32): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Alpha Teknova, Inc. — and when they’d sell — is the membership.

Wall Street

TKNO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TKNO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26TKNOHigh $12.00Median $8.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $7.00Median $8.00High $12.00

The green dot is the last close — the median target sits +23.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026Roth CapitalInitiatesBuy$7.00
10 July 2024Stephens & Co.ReiteratesOverweight$5.00
10 July 2024Stephens & Co.ReiteratesOverweight—
14 May 2024Stephens & Co.ReiteratesOverweight—
12 Mar 2024BTIGDowngradeNeutral—
12 July 2023KeybancInitiatesSector Weight—
29 June 2023BTIGAssumesBuy$6.00
11 Aug 2022Stephens & Co.MaintainsOverweight—
16 Mar 2022Stephens & Co.MaintainsOverweight—
20 July 2021BTIGInitiatesBuy—
20 July 2021Cowen & Co.InitiatesOutperform—
20 July 2021Stephens & Co.InitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TKNO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Alpha Teknova, Inc. (TKNO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−20.2×

Cheaper than 96% of US stocks

Price / sales
7.9×

Cheaper than 17% of US stocks

Price / book
5.0×

Cheaper than 22% of US stocks

EV / EBITDA
−39.7×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
18.5%

Higher than 68% of US stocks

Earnings growth (YoY)
18.5%

Higher than 58% of US stocks

Gross margin
40.1%

Higher than 51% of US stocks

Operating margin
−23.7%

Higher than 21% of US stocks

Net margin
−38.4%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−24.2%

Higher than 29% of US stocks

Return on assets
−9.3%

Higher than 27% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TKNO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TKNOAlpha Teknova, Inc.$346.3M
94
ANIKAnika Therapeutics, Inc.$287.0M
100
KMDAKamada Ltd.$426.4M
77
CGCCanopy Growth Corp.$438.3M
45
AQSTAquestive Therapeutics, Inc.$476.6M
57
EBSEmergent BioSolutions, Inc.$250.6M
87
AKBAAkebia Therapeutics, Inc.$243.7M
74
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TKNO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TKNO news & analysis

Alpha Teknova Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Alpha Teknova reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million, its highest quarterly revenue in the company's 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half of 2026.

Why it matters — The record quarterly revenue and raised full-year outlook signal stronger-than-expected operational performance for TKNO watchers.

Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Alpha Teknova, Inc. held its Q2 2026 earnings call and the transcript of that call has been published on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and related discussion.

Why it matters — TKNO watchers would want to review the Q2 2026 earnings call transcript to see the company's latest quarterly results and management commentary.

Teknova Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 5 Aug 2026positive

Alpha Teknova reported second quarter 2026 financial results with total revenue of $12.2 million, up 18% over the same quarter in the prior year. The company raised its 2026 revenue guidance to $45-47 million and launched its proprietary AI-powered Build-Tek™ custom order configurator to speed developers' path from preclinical to clinical manufacturing.

Why it matters — A TKNO watcher would care because the company reported double-digit revenue growth, raised its full-year revenue guidance, and introduced a new product aimed at streamlining customer workflows.

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

GlobeNewsWire · 5 Aug 2026positive

Teknova launched Build-Tek™, an AI-powered custom order configurator that allows therapy and diagnostics developers to design complex custom products and submit a request for quote in minutes.

Why it matters — Build-Tek™ could streamline Teknova's custom product ordering process and potentially reduce friction for customers, which may support demand for its critical reagents.

FAQ

Frequently asked questions about TKNO stock

What is the TKNO stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Alpha Teknova, Inc. have a median 12-month price target of $8, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TKNO stock a buy right now?

Of the 7 analysts covering Alpha Teknova, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alpha Teknova, Inc. 94 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TKNO?

As at 8 Aug 2026, Alpha Teknova, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).

Will TKNO stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +23.3% from the last close, and Ticker Nerd's factor model ranks Alpha Teknova, Inc. 94 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TKNO stock forecast for 2030?

No analyst covering Alpha Teknova, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TKNO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.

How has TKNO stock performed over the past year?

Alpha Teknova, Inc. returned +49.5% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alpha Teknova, Inc. do?

Alpha Teknova, Inc. is a biotechnology company that specializes in developing and manufacturing critical reagents and materials used in various stages of scientific research and production.

What is the latest news on TKNO?

The most recent item we track (MarketBeat, 6 Aug 2026): "Alpha Teknova Q2 Earnings Call Highlights". Alpha Teknova reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million, its highest quarterly revenue in the company's 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half of 2026.

Company

About Alpha Teknova, Inc.

Alpha Teknova, Inc. is a biotechnology company that specializes in developing and manufacturing critical reagents and materials used in various stages of scientific research and production. Primarily serving the life sciences industry, the company's offerings include media and buffers, liquid-handling tools, and molecular components essential for laboratory assays and diagnostic tests. Alpha Teknova plays a crucial role in supporting pharmaceutical companies, diagnostics firms, and academic institutions, facilitating advancements in research and development. The company’s products are vital in applications such as cell culture, protein and nucleic acid detection, and high-throughput screening. By providing customized and high-quality solutions, Alpha Teknova helps optimize workflows in laboratories, thus accelerating innovation and discovery in the biotechnology sector. Through its contributions, the company is an integral part of the supply chain that underpins scientific breakthroughs and medical advancements.

CEO Mr. Stephen Gunstream · 158 employees · United States · https://www.teknova.com